MX2019011660A - Anticuerpos biespecificos que se unen al receptor 2 del factor de crecimiento humano (erbb-2) y receptor 3 del factor de crecimiento humano (erbb3) para usarse en el tratamiento de celulas que tienen un gen de fusion de neuregulina-1 (nrg1). - Google Patents

Anticuerpos biespecificos que se unen al receptor 2 del factor de crecimiento humano (erbb-2) y receptor 3 del factor de crecimiento humano (erbb3) para usarse en el tratamiento de celulas que tienen un gen de fusion de neuregulina-1 (nrg1).

Info

Publication number
MX2019011660A
MX2019011660A MX2019011660A MX2019011660A MX2019011660A MX 2019011660 A MX2019011660 A MX 2019011660A MX 2019011660 A MX2019011660 A MX 2019011660A MX 2019011660 A MX2019011660 A MX 2019011660A MX 2019011660 A MX2019011660 A MX 2019011660A
Authority
MX
Mexico
Prior art keywords
erbb
treatment
cells
fusion gene
bispecific antibodies
Prior art date
Application number
MX2019011660A
Other languages
English (en)
Spanish (es)
Inventor
Throsby Mark
Logtenberg Ton
Anna Wilhelmina Geuijen Cecilia
Andre Baptiste Maussang-Detaille David
Original Assignee
Merus Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus Nv filed Critical Merus Nv
Publication of MX2019011660A publication Critical patent/MX2019011660A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2019011660A 2017-03-31 2018-04-03 Anticuerpos biespecificos que se unen al receptor 2 del factor de crecimiento humano (erbb-2) y receptor 3 del factor de crecimiento humano (erbb3) para usarse en el tratamiento de celulas que tienen un gen de fusion de neuregulina-1 (nrg1). MX2019011660A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17164292 2017-03-31
PCT/NL2018/050206 WO2018182422A1 (en) 2017-03-31 2018-04-03 Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene

Publications (1)

Publication Number Publication Date
MX2019011660A true MX2019011660A (es) 2019-11-18

Family

ID=58488840

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019011660A MX2019011660A (es) 2017-03-31 2018-04-03 Anticuerpos biespecificos que se unen al receptor 2 del factor de crecimiento humano (erbb-2) y receptor 3 del factor de crecimiento humano (erbb3) para usarse en el tratamiento de celulas que tienen un gen de fusion de neuregulina-1 (nrg1).

Country Status (14)

Country Link
US (3) US11780925B2 (https=)
EP (1) EP3600413A1 (https=)
JP (2) JP7737220B2 (https=)
KR (2) KR20260006707A (https=)
CN (1) CN110650752A (https=)
AU (1) AU2018246873B2 (https=)
BR (1) BR112019020508A2 (https=)
CA (1) CA3058343A1 (https=)
EA (1) EA201992063A1 (https=)
IL (2) IL269656B2 (https=)
MX (1) MX2019011660A (https=)
PH (1) PH12019550202A1 (https=)
SG (1) SG11201908971RA (https=)
WO (1) WO2018182422A1 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015130173A1 (en) * 2014-02-28 2015-09-03 Merus B.V. Antibody that binds erbb-2 and erbb-3
JP6771385B2 (ja) 2014-02-28 2020-10-21 メルス ナムローゼ フェンノートシャップ 二重特異性抗体および医薬組成物
SMT202100230T1 (it) 2015-10-23 2021-07-12 Fundacio Inst De Recerca Biomedica Irb Barcelona Molecole di legame che inibiscono la crescita tumorale
US20200291130A1 (en) * 2017-03-31 2020-09-17 Merus N.V. Antibodies for the treatment of erbb-2/erbb-3 positive tumors
IL269656B2 (en) * 2017-03-31 2024-06-01 Merus Nv Bispecific antibodies that bind ERBB-2 and ERBB3 for use in the treatment of cells with NRG1 fusion gene
JP7296891B2 (ja) 2017-05-17 2023-06-23 メルス ナムローゼ フェンノートシャップ 乳癌のためのＥｒｂＢ－２／ＥｒｂＢ－３二重特異性抗体と内分泌療法との組み合わせ
SG11202001050PA (en) 2017-08-09 2020-03-30 Merus Nv Antibodies that bind egfr and cmet
MA52212A (fr) * 2018-03-30 2021-02-17 Merus Nv Anticorps multivalent
CN114426578B (zh) * 2019-02-14 2025-03-21 美勒斯公司 结合egfr、her2及her3的结合部分的组合
CN113677701B (zh) * 2019-03-29 2025-02-07 豪夫迈·罗氏有限公司 产生亲合结合多特异性抗体的方法
GB201913079D0 (en) 2019-09-11 2019-10-23 Hummingbird Bioscience Holdings Pte Ltd Treatment and prevention of cancer using her3 antigen-binding molecules
JP7532514B2 (ja) * 2019-10-24 2024-08-13 メルス ナムローゼ フェンノートシャップ Ｈｅｒ２及びｈｅｒ３陽性癌に罹患している対象を治療するための手段及び方法
CN115362270A (zh) 2020-01-29 2022-11-18 得克萨斯州大学系统董事会 Egfr/her2酪氨酸激酶抑制剂和/或her2/her3抗体在具有nrg1融合的癌症的治疗中的用途
JP7777533B2 (ja) * 2020-01-29 2025-11-28 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｎｒｇ１融合体を有するがんの治療のためのポジオチニブの使用
KR20220148200A (ko) 2020-02-28 2022-11-04 리제너론 파마슈티칼스 인코포레이티드 Her2에 결합하는 이중특이적 항원 결합 분자 및 이의 사용 방법
CN115843256B (zh) * 2020-10-15 2026-03-06 上海翰森生物医药科技有限公司 抗erbb3抗体或其抗原结合片段及其医药用途
WO2022098233A1 (en) * 2020-11-04 2022-05-12 Merus N.V. Means and methods for treating subjects with erbb3 mutation positive cancer
US12551584B1 (en) 2020-12-07 2026-02-17 Actinium Pharmaceuticals, Inc. Lewis Y radioimmunotherapy for the treatment of cancer
EP4304636A1 (en) * 2021-03-11 2024-01-17 Elevation Oncology, Inc. Dosage and administration of anti-erbb3 (her3) monoclonal antibodies to treat tumors associated with neuregulin 1 (nrg1) gene fusions
TW202313987A (zh) * 2021-06-03 2023-04-01 荷蘭商美勒斯公司 用於測定nrg1融合多核苷酸的液態檢體測定法
GB202108449D0 (en) 2021-06-14 2021-07-28 Hummingbird Bioscience Holdings Pte Ltd Cells expressing her3 antigen-binding molecules
JP2024536719A (ja) 2021-09-03 2024-10-08 キャンサー・リサーチ・テクノロジー・リミテッド Ｈｅｒ３抗原結合性分子を使用したがんの処置および予防
CN114410776B (zh) * 2021-12-21 2023-08-25 南京世和医疗器械有限公司 一种nrg1融合基因的检测方法及试剂盒
WO2024121163A1 (en) 2022-12-06 2024-06-13 Cancer Research Technology Limited Combination of 10d1f and an androgen inhibitor for treatment and prevention of cancers
CN120417924A (zh) 2022-12-07 2025-08-01 蜂鸟生物科技私人有限公司 治疗和预防癌症的组合疗法
WO2024147097A1 (en) 2023-01-03 2024-07-11 Hummingbird Bioscience Pte. Ltd. Her3-binding antibody-drug conjugate
EP4687972A1 (en) 2023-04-06 2026-02-11 Hummingbird Bioscience Pte. Ltd. Treatment and prevention of cancer using her3 antigen-binding molecules
KR20260022498A (ko) 2023-04-14 2026-02-19 허밍버드 바이오사이언스 피티이. 엘티디. 암의 치료 및 예방을 위한 조합물
WO2025056781A1 (en) 2023-09-15 2025-03-20 Hummingbird Bioscience Pte. Ltd. Treatment and prevention of cancer using her3-binding molecules
WO2026025013A2 (en) 2024-07-26 2026-01-29 Pfizer Inc. Combination therapy using cdk4 inhibitors for cancer treatments

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4801687A (en) 1986-10-27 1989-01-31 Bioprobe International, Inc. Monoclonal antibody purification process using protein A
FI884924L (fi) 1987-10-28 1989-04-29 Oncogen Humanimmuglobulin som producerats med hybrid-dna-teknik.
US5151504A (en) 1989-11-17 1992-09-29 E. R. Squibb & Sons, Inc. Method for purification of monoclonal antibodies
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
EP0523949B1 (en) 1991-07-15 2003-06-25 The Wellcome Foundation Limited Production of antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
ATE299938T1 (de) 1997-05-02 2005-08-15 Genentech Inc Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
HK1048138B (zh) 1999-04-15 2009-06-12 荷兰克鲁塞尔公司 用编码腺病毒e1蛋白的序列在人体细胞中生产重组蛋白
US20070111201A1 (en) 2001-04-30 2007-05-17 Benjamin Doranz Reverse transfection of cell arrays for structural and functional analyses of proteins
PT1600510E (pt) 2001-07-04 2007-06-25 Chromagenics Bv Sequências de adn com actividade anti-repressora.
US7332580B2 (en) 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
WO2003107218A1 (ja) 2002-05-31 2003-12-24 セレスター・レキシコ・サイエンシズ株式会社 相互作用予測装置
DK2314629T4 (da) 2002-07-18 2023-02-06 Merus Nv Rekombinant produktion af blandinger af antistoffer
SI1583830T1 (sl) 2003-01-07 2006-12-31 Symphogen As Postopek za pripravo rekombinantnih poliklonskih proteinov
EP2322547A1 (en) 2003-06-25 2011-05-18 Crucell Holland B.V. Myeloid cell-specific lectin
BRPI0510716A (pt) 2004-05-05 2007-11-20 Merrimack Pharmaceuticals Inc uso de um agente de ligação bi-especìfico, agente de ligação bi-especìfico, composição de um agente de ligação bi-especìfico, e, kit
CA2569509C (en) 2004-06-03 2014-08-12 Novimmune S.A. Anti-cd3 antibodies and methods of use thereof
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CA2599606A1 (en) 2005-02-23 2006-08-31 Merrimack Pharmaceuticals, Inc. Bispecific binding agents for modulating biological activity
US20060212956A1 (en) 2005-03-14 2006-09-21 Genentech, Inc. Animal model of ligand activated HER2 expressing tumors
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
PT1999154E (pt) 2006-03-24 2013-01-24 Merck Patent Gmbh Domínios proteicos heterodiméricos modificados
JP2009541275A (ja) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス 二重特異性抗体の生産
WO2008027236A2 (en) 2006-08-30 2008-03-06 Genentech, Inc. Multispecific antibodies
US8290739B2 (en) 2006-10-20 2012-10-16 Amfit, Inc. Method for determining relative mobility of regions of an object
WO2008140493A2 (en) 2006-11-21 2008-11-20 The Regents Of The University Of Californina Anti-egfr family antibodies, bispecific anti-egfr family antibodies and methods of use thereof
KR101598229B1 (ko) 2007-02-16 2016-02-26 메리맥 파마슈티컬즈, 인크. Ｅｒｂｂ3에 대한 항체 및 이의 용도
ES2593484T3 (es) 2007-03-29 2016-12-09 Genmab A/S Anticuerpos biespecíficos y métodos de producción de los mismos
MX2009010611A (es) 2007-04-03 2010-03-26 Micromet Ag Enlazadores biespecificos, especificos para especies.
US7705103B2 (en) 2007-06-22 2010-04-27 3M Innovative Properties Company Polydiorganosiloxane polyoxamide copolymers
EP2173379B2 (en) 2007-07-02 2023-07-05 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer
US8536310B2 (en) 2007-10-17 2013-09-17 Arca Biopharma, Inc. Antibodies to CLL-1
EP2235536A4 (en) 2007-12-20 2011-05-04 Lab Corp America Holdings HER-2-DIAGNOSTIC PROCEDURE
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
AU2009211148B2 (en) 2008-02-05 2014-08-28 Zymeworks Inc. Methods for determining correlated residues in a protein or other biopolymer using molecular dynamics
EP2147594B1 (en) 2008-06-27 2013-11-13 Merus B.V. Antibody producing non-human mammals
WO2010022736A2 (en) 2008-08-29 2010-03-04 Symphogen A/S Recombinant anti-epidermal growth factor receptor antibody compositions
WO2010059315A1 (en) 2008-11-18 2010-05-27 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
EP2387711B1 (en) 2009-01-15 2015-04-22 Laboratory Corporation of America Holdings Methods of determining patient response by measurement of her-3
CN104262483A (zh) 2009-01-26 2015-01-07 根马布股份公司 用于生成抗体混合物的方法
MY152068A (en) 2009-03-20 2014-08-15 Genentech Inc Bispecific anti-her antibodies
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
MY192182A (en) 2009-06-26 2022-08-04 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
EA201200195A1 (ru) 2009-08-21 2012-12-28 Мерримаск Фармасьютикалс, Инк. АНТИТЕЛА ПРОТИВ ЭКТОДОМЕНА ErbB3 И ИХ ПРИМЕНЕНИЕ
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
EP2496598B1 (en) 2009-11-04 2017-08-02 Affibody AB Her3 binding polypeptides
EA034462B1 (ru) 2009-11-24 2020-02-11 Алетиа Байотерапьютикс Инк. Антикластериновые антитела и антигенсвязывающие фрагменты и их использование для уменьшения объема новообразований
SMT202600080T1 (it) 2010-02-08 2026-03-09 Regeneron Pharma Topo con catena leggera comune
US20130185821A1 (en) 2010-02-08 2013-07-18 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
CN103261220B (zh) 2010-08-16 2016-06-15 诺夫免疫股份有限公司 用于生成多特异性和多价抗体的方法
AU2011290672B2 (en) 2010-08-20 2015-07-09 Novartis Ag Antibodies for epidermal growth factor receptor 3 (HER3)
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
ES2758994T3 (es) 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
CN103547598A (zh) 2011-02-24 2014-01-29 梅里麦克制药股份有限公司 包含抗-erbb3药剂的联合治疗
US20140134170A1 (en) 2011-03-11 2014-05-15 Merrimack Pharmaceuticals, Inc. Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers
MX2013010444A (es) 2011-03-15 2014-03-21 Merrimack Pharmaceuticals Inc Superar la resistencia a inhibidores de la via erbb.
BR112013023918A2 (pt) 2011-03-25 2016-12-13 Glenmark Pharmaceuticals Sa imunoglobulina hetero-dimérica ou fragmento hetero-dimérico da mesma, método para produzir uma imunoglobulina hetero-dimérica ou fragmento hetero-dimérico da mesma, método para construir uma interface proteína-proteína de um domínio de uma proteína de múltiplos domínios e uso de um domínio doador de um primeiro e de um segundo membro de uma super-família de imunoglobulina de ocorrência natural
NO2707391T3 (https=) 2011-05-13 2018-04-07
JPWO2012176779A1 (ja) 2011-06-20 2015-02-23 協和発酵キリン株式会社 抗ｅｒｂＢ３抗体
US9567827B2 (en) 2013-07-15 2017-02-14 Downhole Technology, Llc Downhole tool and method of use
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
PH12014500483A1 (en) 2011-09-30 2014-04-14 Regeneron Pharma Anti-erbb3 antibodies and uses thereof
DK2797957T3 (da) 2011-11-23 2019-09-23 Medimmune Llc Bindingsmolekyler specifikke for her3 og anvendelser deraf
CN104093742A (zh) 2011-12-05 2014-10-08 诺华股份有限公司 抗her3的结构域iii和结构域iv的表皮生长因子受体3(her3)抗体
EP3590538A1 (en) 2011-12-05 2020-01-08 Novartis AG Antibodies for epidermal growth factor receptor 3 (her3)
EP2823270B1 (en) 2012-03-09 2022-05-04 Promega Corporation pH SENSORS
US20130259867A1 (en) 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
AR090549A1 (es) 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
US9248181B2 (en) 2012-04-20 2016-02-02 Merus B.V. Methods and means for the production of Ig-like molecules
TWI641619B (zh) 2012-06-25 2018-11-21 美商再生元醫藥公司 抗－ｅｇｆｒ抗體及其用途
HUE042040T2 (hu) 2012-09-27 2019-06-28 Merus Nv Bispecifikus IGG antitestek mint T-sejt kapcsolók
WO2014060365A1 (en) 2012-10-15 2014-04-24 Universität Zürich Prorektorat Mnw Bispecific her2 ligands for cancer therapy
MX361088B (es) 2012-11-21 2018-11-26 Janssen Biotech Inc Anticuerpos del receptor del factor de crecimiento epidérmico aislado/del receptor del factor de crecimiento de hepatocitos (egfr/c-met) biespecíficos.
AU2014212081A1 (en) 2013-02-04 2015-08-13 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a Wnt pathway inhibitor
CA2900955A1 (en) 2013-03-14 2014-10-02 Oncomed Pharmaceuticals, Inc. Met-binding agents and uses thereof
US20160041171A1 (en) 2013-04-05 2016-02-11 Laboratory Corporation Of America Holdings Systems and methods for facilitating diagnosis, prognosis and treatment of cancer based on detection of her3 activation
WO2014182970A1 (en) 2013-05-08 2014-11-13 Zymeworks Inc. Bispecific her2 and her3 antigen binding constructs
WO2014197854A1 (en) 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Novel linkers for antibody-drug conjugates and related compounds, compositions, and methods of use
US9879081B2 (en) 2013-06-25 2018-01-30 Samsung Electronics Co., Ltd. Protein complex, bispecific antibody including the protein complex, and method of preparation thereof
EP3030577B1 (en) * 2013-08-07 2019-10-02 Universität zu Köln Novel nrg1 fusion genes in cancer
US9551208B2 (en) 2013-08-26 2017-01-24 Halliburton Energy Services, Inc. Identifying uncertainty associated with a stimulated reservoir volume (SRV) calculation
US10519247B2 (en) 2013-11-01 2019-12-31 Board Of Regents,The University Of Texas System Targeting HER2 and HER3 with bispecific antibodies in cancerous cells
WO2015130173A1 (en) * 2014-02-28 2015-09-03 Merus B.V. Antibody that binds erbb-2 and erbb-3
JP6771385B2 (ja) 2014-02-28 2020-10-21 メルス ナムローゼ フェンノートシャップ 二重特異性抗体および医薬組成物
CA2944649C (en) 2014-04-04 2022-06-21 Bionomics, Inc. Humanized antibodies that bind lgr5
US10813952B2 (en) 2014-11-14 2020-10-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services NK cells with an increased antibody-dependent cellular toxicity (ADCC) against tumors
MA41123A (fr) 2014-12-02 2017-10-10 Oncomed Pharm Inc Polythérapie pour le traitement du cancer
WO2016201454A1 (en) 2015-06-12 2016-12-15 The Translational Genomics Research Institute Targeted therapies for cancer
US9914777B2 (en) 2015-07-10 2018-03-13 Merus N.V. Human CD3 binding antibody
SMT202100230T1 (it) 2015-10-23 2021-07-12 Fundacio Inst De Recerca Biomedica Irb Barcelona Molecole di legame che inibiscono la crescita tumorale
US20200291130A1 (en) 2017-03-31 2020-09-17 Merus N.V. Antibodies for the treatment of erbb-2/erbb-3 positive tumors
IL269656B2 (en) 2017-03-31 2024-06-01 Merus Nv Bispecific antibodies that bind ERBB-2 and ERBB3 for use in the treatment of cells with NRG1 fusion gene
JP7296891B2 (ja) 2017-05-17 2023-06-23 メルス ナムローゼ フェンノートシャップ 乳癌のためのＥｒｂＢ－２／ＥｒｂＢ－３二重特異性抗体と内分泌療法との組み合わせ
SG11202001050PA (en) 2017-08-09 2020-03-30 Merus Nv Antibodies that bind egfr and cmet

Also Published As

Publication number Publication date
AU2018246873B2 (en) 2021-05-06
US20200102393A1 (en) 2020-04-02
US12247078B2 (en) 2025-03-11
JP7737220B2 (ja) 2025-09-10
EA201992063A1 (ru) 2020-03-26
JP2020511993A (ja) 2020-04-23
CA3058343A1 (en) 2018-10-04
SG11201908971RA (en) 2019-10-30
IL269656B2 (en) 2024-06-01
US20240182587A1 (en) 2024-06-06
KR102905513B1 (ko) 2026-01-02
US11780925B2 (en) 2023-10-10
US20240199747A1 (en) 2024-06-20
AU2018246873A1 (en) 2019-10-17
KR20190140945A (ko) 2019-12-20
EP3600413A1 (en) 2020-02-05
PH12019550202A1 (en) 2020-07-13
IL269656B1 (en) 2024-02-01
KR20260006707A (ko) 2026-01-13
IL310223A (en) 2024-03-01
NZ757560A (en) 2024-10-25
JP2025109785A (ja) 2025-07-25
WO2018182422A1 (en) 2018-10-04
IL269656A (en) 2019-11-28
WO2018182422A8 (en) 2019-10-31
BR112019020508A2 (pt) 2020-08-04
CN110650752A (zh) 2020-01-03

Similar Documents

Publication Publication Date Title
MX2019011660A (es) Anticuerpos biespecificos que se unen al receptor 2 del factor de crecimiento humano (erbb-2) y receptor 3 del factor de crecimiento humano (erbb3) para usarse en el tratamiento de celulas que tienen un gen de fusion de neuregulina-1 (nrg1).
ZA202107931B (en) Anti-tau antibodies and methods of use
CO2020016619A2 (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso
MX2024013963A (es) Un antagonista de il-4r util para el tratamiento o la prevencion del asma
MX2019013072A (es) Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1.
MX2021002970A (es) Proteinas de union a nkg2d, cd16 y un antigeno asociado a tumor.
PH12018501281A1 (en) Human immunodeficiency virus neutralizing antibodies
MX2016013457A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
CL2017003006A1 (es) Métodos de acondicionamiento de pacientes para tratamiento con linfocitos t
CO2018001149A2 (es) Anticuerpos monoclonales contra bcma
ECSP18096095A (es) Anticuerpos a la alfa-sinucleína y usos de los mismos
MX370480B (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades.
EA201790545A1 (ru) Антитела и иммуноконъюгаты против her2
EA201691866A1 (ru) Проникающие в опухоль лимфоциты для адоптивной клеточной терапии
CU24498B1 (es) Anticuerpos de factor xi
CY1125150T1 (el) Ενωσεις φαινυλο-2-υδροξυ-ακετυλαμινο-2-μεθυλο-φαινυλιου
MX2017008456A (es) Compuestos biciclicos fusionados para el tratamiento de enfermedades.
CL2019002251A1 (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos.
PH12018500887A1 (en) Anti-htra1 antibodies and methods of use thereof
EA201890442A1 (ru) Получение фоторецепторов для лечения заболеваний сетчатки
HK1255056A1 (zh) 抗cd115抗体
MA40535A (fr) Imagerie et thérapie d'une inflammation et d'une infection ciblant hsp90
EA201890457A1 (ru) Комбинации антитела против ox40 и модулятора tlr4 и их применение
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
CO2017010621A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades